Breast Density

Breast density, or fibroglandular density, is found through breast imaging and varies based on the amount of fat to the amount of connective tissue. About 50 percent of women have what is referred to as dense breasts, where the tissue appears white on mammograms and can hide cancers, which also appear white. Women with very dense breasts may need to undergo supplemental imaging that can see through dense breast tissue, such as breast ultrasound, breast MRI or nuclear imaging. Many U.S. states now have legislation requiring radiologists to inform patients if they have dense breasts. Some states also now require insurance companies to cover supplemental imaging  in these patients. Breast density is graded into 4 classes, or BI-RAD scores, to explain the level of density in the radiology report. 

Volpara Health, a global health technology software leader providing an integrated breast care platform for the delivery of personalized breast care, has signed an agreement with Invitae Corporation, a leader in medical genetics, to bring Invitae's genetic testing services to Volpara's customers in the United States. 
News | Breast Imaging | July 29, 2021
July 29, 2021 — Volpara Health, a global health technology software leader providing an integrated breast care platform...
According to ARRS’ American Journal of Roentgenology (AJR), return to routine screening for BI-RADS 3 lesions on supplemental automated whole-breast US (ABUS) substantially reduces the recall rate, while being unlikely to result in adverse outcome

Normal right mediolateral oblique (A) and craniocarudal (B) view screening mammograms demonstrate density C breasts. Coronal (C), transverse (D), and reconstructed lateral (E) views from supplemental automatic breast ultrasound (ABUS) demonstrates 7 mm circumscribed slightly hypoechoic circumscribed lesion at 11 o’clock position in right breast. Lesion was classified as BI-RADS 3. Patient has undergone yearly mammograms for 4 years following the ABUS examination with no breast cancer diagnosis.

News | Breast Imaging | July 16, 2021
July 16, 2021 —According to ARRS’ American Journal of Roentgenology (AJR), return to routine screening for BI-RADS 3...
Volpara now holds 98 granted patents across 27 countries
News | Breast Imaging | July 16, 2021
July 16, 2021 — Volpara has recently been granted another patent by the European Patent Office, raising the total...
The prevalence of genetic mutations associated with breast cancer in Black and white women is the same, according to a new JAMA Oncology study of nearly 30,000 patients led by researchers in the Basser Center for BRCA at the Abramson Cancer Center.

Getty Images

News | Women's Health | June 15, 2021
June 15, 2021 — The prevalence of genetic mutations associated with breast cancer in Black and white women is the same...
Kathryn A. Gold, M.D., associate clinical professor at University of California San Diego School of Medicine, presented data showing an increase in people diagnosed with advanced stage breast cancer in 2020 and 2021, compared to 2019.

Kathryn A. Gold, M.D., associate clinical professor at University of California San Diego School of Medicine, presented data showing an increase in people diagnosed with advanced stage breast cancer in 2020 and 2021, compared to 2019.

News | Breast Imaging | June 08, 2021
June 8, 2021 — Reporting at the 2021 annual meeting of the American Society of Clinical Oncology, Kathryn A. Gold, M.D...
Medical researchers at Flinders University have established a new link between high body mass index (BMI) and breast cancer survival rates — with clinical data revealing worse outcomes for early breast cancer (EBC) patients and improved survival rates in advanced breast cancer (ABC).

Getty Images

News | Women's Health | May 13, 2021
May 13, 2021 — Medical researchers at Flinders University have established a new link between high body mass index (BMI...
Hologic, Inc. launched Project Health Equality (PHE), a unique initiative that strives to address the structural and cultural barriers that prevent Black and Hispanic women in the U.S. from receiving the same quality health care as white women.
News | Women's Health | May 12, 2021
May 12, 2021 — Hologic, Inc. launched Project Health Equality (PHE), a unique initiative that strives to address the...
News | Artificial Intelligence | May 11, 2021
May 11, 2021 — Whiterabbit, an AI technology company focused on early breast cancer detection, today announced the...
Knowledge gaps regarding breast density among women’s health providers can be addressed with web-based education and may lead to more informed and effective patient-provider communications
News | Breast Density | April 28, 2021
April 28, 2021 – DenseBreast-info.org (DB-I) announced the results of the study, “Effect of an educational intervention...
The Imagio Breast Imaging System combines laser light and sound with conventional ultrasound technology to provide fused functional and anatomic images (referred to as optoacoustic/ultrasound or OA/US) in real time, increasing confidence in diagnostic accuracy.

The Imagio Breast Imaging System combines laser light and sound with conventional ultrasound technology to provide fused functional and anatomic images (referred to as optoacoustic/ultrasound or OA/US) in real time, increasing confidence in diagnostic accuracy.

News | Breast Imaging | April 23, 2021
April 23, 2021 — The U.S. Food and Drug Administration (FDA) has approved Seno Medical's Imagio P200003 Breast Imaging...
 iCad announced that ProFound AI Version 3.0 for Digital Breast Tomosynthesis (DBT) was cleared by the U.S. Food and Drug Administration (FDA).
News | Breast Imaging | March 23, 2021
March 23, 2021 — iCad announced that ProFound AI Version 3.0 for Digital Breast Tomosynthesis (DBT) was cleared by the...
Left to right: Subtraction right mediolateral oblique (MLO) CEM was non-diagnostic because of artifact, potentially due to motion misregistration from extended exposure time; subtraction right MLO implant displaced CEM image shows 5.8 cm enhancing mass (arrow); contrast-enhanced MRI sagittal subtraction image shows concordant mass (arrow).

Left to right: Subtraction right mediolateral oblique (MLO) CEM was non-diagnostic because of artifact, potentially due to motion misregistration from extended exposure time; subtraction right MLO implant displaced CEM image shows 5.8 cm enhancing mass (arrow); contrast-enhanced MRI sagittal subtraction image shows concordant mass (arrow).

News | Breast Imaging | March 18, 2021
March 18, 2021 — According to ARRS’ American Journal of Roentgenology (AJR), contrast-enhanced mammography (CEM) showed...
Attending the two most recent screening appointments before a breast cancer diagnosis protects against breast cancer death, according to a Queen Mary University of London study of over half a million Swedish women conducted over 24 years

Getty Images

News | Breast Imaging | March 12, 2021
March 12, 2021 — For women who had participated in both of their previous two screening examinations, the incidence of...
Breast cancer is the most common fatal cancer in women. Early detection increases a woman's chances of recovery. Magnetic Resonance Imaging (MRI) is an accurate technique for detecting and classifying tumors in breast tissue.
News | MRI Breast | March 09, 2021
March 9, 2021 — Breast cancer is the most common fatal cancer in women. Early detection increases a woman's chances of...
A comparison of standard mammography imaging (left) in a woman with dense breasts and a breast MRI imaging study (right) showing a clearly defined cancer and is extremely hard to detect on the mammograms.

A comparison of standard mammography imaging (left) in a woman with dense breasts and a breast MRI imaging study (right) showing a clearly defined cancer and is extremely hard to detect on the mammograms. Images from Christiane Kuhl, M.D.

Feature | MRI Breast | March 04, 2021 | By Dave Fornell, Editor
Dense breast tissue can hide cancers in mammograms in about half of women. Supplemental imaging is often needed to...
Researchers said women who skip even one scheduled mammography screening before a breast cancer diagnosis face a significantly higher risk of dying from the cancer.

Getty Images

News | Mammography | March 03, 2021
March 3, 2021 — Attendance at regular mammography screening substantially reduces the risk of dying from breast cancer...
55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned. #COVIDvaccine #COVID19

55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned.

News | Breast Imaging | February 24, 2021
February 24, 2021 — An open-access article in ARRS’ American Journal of Roentgenology (AJR) describes the clinical and...
Breast Cancer Index added to National Comprehensive Cancer Network guidelines to predict benefit from extended endocrine therapy
News | Women's Health | February 23, 2021
February 23, 2021 — Hologic, Inc. has completed its previously announced acquisition of molecular oncology leader...
Screening strategy based on baseline breast density at age 40 may be effective and cost-effective for reducing breast cancer mortality

Getty Images

News | Breast Density | February 10, 2021
February 10, 2021 — A mammography screening strategy based on a baseline breast density measure at age 40 may be the...
Comparison of breast cancer mortality rates (red squares) and distant-stage breast cancer incidence rates from SEER9 (blue dots) and SEER18 (green dots) per 100,000 for white women aged, A, 20–39, B, 40–69, and, C, 70–79 years (3,7,8).

Comparison of breast cancer mortality rates (red squares) and distant-stage breast cancer incidence rates from SEER9 (blue dots) and SEER18 (green dots) per 100,000 for white women aged, A, 20–39, B, 40–69, and, C, 70–79 years (3,7,8). Image courtesy of Radiology 

News | Breast Imaging | February 10, 2021
February 10, 2021 — Breast cancer death rates have stopped declining for women in the U.S. younger than age 40, ending...